Rituximab (Rituxan)

- Rituximab is used for many autoimmune diseases, such as rheumatoid arthritis and multiple sclerosis, as well as cancer.

- It binds CD20 on B cells, which results in recruitment of other immune cells and destruction of the B cells.

- It is administered through intravenous infusion every 6 months.

- Sales in 2016 were €1.4 billion in Europe.

- It has a very low immunogenicity rates, only about 10%.

Labs that test for drug level:

Karolinska University Lab 
University of Tours
San Luigi Gonzaga University Hospital

Labs that test for ADA titre: 

Karolinska Institutet
San Luigi Gonzaga University Hospital